AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (959.8 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Basic Study | Publishing Language: Chinese | Open Access

Relationship between serum miR-199a-5p and miR-378a-3p levels and recurrence of infants with proliferative facial hemangioma after propranolol withdrawal

Yan GUO1Kai ZHANG2Xuhui FAN3Lifeng LI4( )
Department of Dental Emergency, Xi'an Jiaotong University Hospital of Stomatology, Xi'an 710001, China
Department of Plastic Surgery, Hospital of Stomatology, Air Force Military Medical University, Xi'an 710032, China
Department of Oral and Maxillofacial Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
Department of Traumatology and Plastic Surgery, Hospital of Stomatology, Xi'an Jiaotong University, Xi'an 710001, China
Show Author Information

Abstract

Objective

To investigate the relationship between serum miR-199a-5p and miR-378a-3p levels and the recurrence of infants with proliferative facial hemangioma relapsed after propranolol withdrawal in infants.

Methods

Ninety-three infants with proliferative facial hemangioma were selected, all of whom received propranolol treatment. The recurrence of the hemangioma after treatment was followed up, and the children were divided into a recurrence group (23 patients) and a nonrecurrence group (70 patients). Venous blood was collected before and after treatment, and the serum levels of miR-199a-5p and miR-378a-3p were detected by qRT-PCR, and the relationship between the serum levels of miR-199a-5p and miR-378a-3p and the recurrence of proliferative facial hemangioma relapsed after propranolol withdrawal in infants was analyzed.

Results

The serum expressions levels of miR-199a-5p and miR-378a-3p in non-relapsed group were increased after treatment compared with before treatment (P < 0.05), and there was no significant difference in the levels of miR-199a-5p and miR-378a-3p in the serum of the recurrence group after treatment compared with before treatment (P > 0.05). After treatment, the levels of miR-199a-5p and miR-378a-3p in the serum of the recurrence group were lower than those of the nonrecurrence group (P < 0.05). After treatment, the serum levels of miR-199a-5p and miR-378a-3p in patients with Ⅲ ~Ⅳ Norm grade hemangioma were higher than those in patients with Ⅰ~Ⅱ Norm grade hemangioma (P < 0.05). Logistic regression analysis showed that the low expression of miR-199a-5p, low expression of miR-378a-3p and tumor grade Ⅰ~Ⅱ after treatment were risk factors for the recurrence of proliferative facial hemangioma after propranolol withdrawal in infants (P < 0.05).

Conclusion

Low serum levels of miR-199a-5p and miR-378a-3p are associated with the recurrence of proliferative facial hemangioma after propranolol withdrawal in infants.

CLC number: R78 Document code: A Article ID: 2096-1456(2022)02-0097-06

References

【1】
【1】
 
 
Journal of Prevention and Treatment for Stomatological Diseases
Pages 97-102

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
GUO Y, ZHANG K, FAN X, et al. Relationship between serum miR-199a-5p and miR-378a-3p levels and recurrence of infants with proliferative facial hemangioma after propranolol withdrawal. Journal of Prevention and Treatment for Stomatological Diseases, 2022, 30(2): 97-102. https://doi.org/10.12016/j.issn.2096-1456.2022.02.004

4

Views

0

Downloads

0

Crossref

0

Scopus

Received: 09 July 2021
Revised: 25 August 2021
Published: 20 February 2022
© 2022 by Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases